{
  "nct_id": "NCT26724911",
  "indication": "Type 2 Diabetes",
  "phase": "Phase 2",
  "sample_size": 185,
  "duration_weeks": 19,
  "dropout_rate": 0.13,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "Postprandial glucose reduction"
  ],
  "secondary_endpoints": [
    "HbA1c reduction",
    "Fasting glucose reduction"
  ],
  "outcome_summary": "Met all pre-specified efficacy endpoints with favorable safety profile",
  "success": 1,
  "start_date": "2022-09-10",
  "completion_date": "2023-01-21"
}